0
Clinical Investigations: COPD |

Predictors of Survival in Severe, Early Onset COPD*

Craig P. Hersh, MD, MPH; Dawn L. DeMeo, MD, MPH; Essam Al-Ansari, MD, MPH; Vincent J. Carey, PhD; John J. Reilly, MD, FCCP; Leo C. Ginns, MD, FCCP; Edwin K. Silverman, MD, PhD
Author and Funding Information

*From the Channing Laboratory (Drs. Hersh, DeMeo, Al-Ansari, Carey, and Silverman) and Division of Pulmonary and Critical Care Medicine (Dr. Reilly), Department of Medicine, Brigham and Women’s Hospital, Boston, MA; Pulmonary and Critical Care Unit (Dr. Ginns), Department of Medicine, Massachusetts General Hospital, Boston, MA.

Correspondence to: Edwin K. Silverman, MD, PhD, Channing Laboratory, Brigham and Women’s Hospital, 181 Longwood Ave, Boston, MA 02115; e-mail: ed.silverman@channing.harvard.edu



Chest. 2004;126(5):1443-1451. doi:10.1378/chest.126.5.1443
Text Size: A A A
Published online

Study objectives: Multiple risk factors for mortality in patients with COPD have been described, but most studies have involved older, primarily male subjects. The purpose of this study was to determine the mortality rate and predictors of survival in subjects with severe, early onset COPD.

Design, setting, and participants: The cohort of 139 probands in the Boston Early-Onset COPD Study was recruited from lung transplant and general pulmonary clinics between September 1994 and July 2002. Subjects were < 53 years old, had an FEV1 of < 40% of predicted, did not have severe α1-antitrypsin deficiency, and had not undergone lung transplantation. The initial evaluation included a standardized respiratory questionnaire, spirometry, and a blood sample. A follow-up telephone interview was conducted between May and December 2002.

Measurements and results: Subjects were young (mean age at enrollment, 47.9 years) and had severe airflow obstruction (mean baseline FEV1, 19.4% predicted). A total of 72.7% of the subjects were women (p < 0.0001 [comparison to equal gender distribution]). The median estimated survival time was 7.0 years from the time of study enrollment, determined by the Kaplan-Meier method. The majority of deaths were due to cardiorespiratory illness. In a multivariable Cox proportional hazards model, adjusting for age, gender, and baseline FEV1, lifetime cigarette consumption (hazard ratio [HR], 1.20 [per 10 pack-years]; 95% confidence interval [CI], 1.02 to 1.40) and recent smoking status (HR, 2.50; 95% CI, 1.03 to 6.05) were both significant predictors of mortality.

Conclusion: In this cohort, recent smoking status predicted increased mortality independent of the effects of lifetime smoking intensity. Smoking cessation may confer a survival benefit even among patients with very severe COPD.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Non-pharmacological treatments for COPD. Respirology 2016;21(5):791-809.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543